Back to Search
Start Over
Thrombocytopenia in pediatric patients on concurrent cannabidiol and valproic acid
- Source :
- Epilepsia. 61
- Publication Year :
- 2020
- Publisher :
- Wiley, 2020.
-
Abstract
- In January 2019, a new plant-derived purified cannabidiol preparation, approved by the US Food and Drug Administration, became commercially available for patients ≥2 years old with Lennox-Gastaut syndrome or Dravet syndrome. Among our patients who were prescribed the new cannabidiol formulation, we observed several cases of thrombocytopenia and therefore embarked on this study. We conducted a single-center systematic chart review of all pediatric patients (
- Subjects :
- Male
0301 basic medicine
Drug Resistant Epilepsy
medicine.medical_specialty
Adolescent
Side effect
Combination therapy
Epilepsies, Myoclonic
Gastroenterology
Young Adult
03 medical and health sciences
0302 clinical medicine
Dravet syndrome
Internal medicine
medicine
Cannabidiol
Humans
Child
Valproic Acid
Epilepsy
Lennox Gastaut Syndrome
business.industry
Infant
medicine.disease
Thrombocytopenia
Regimen
030104 developmental biology
Neurology
Child, Preschool
Epilepsy syndromes
Anticonvulsants
Drug Therapy, Combination
Female
Neurology (clinical)
business
030217 neurology & neurosurgery
medicine.drug
Lennox–Gastaut syndrome
Subjects
Details
- ISSN :
- 15281167 and 00139580
- Volume :
- 61
- Database :
- OpenAIRE
- Journal :
- Epilepsia
- Accession number :
- edsair.doi.dedup.....2a3b34e02a1203d121e46f237e84b22c